Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial (Q42910105)

11 November 2017

title

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial (English)

1 reference

11 November 2017

1 reference

3

Shinichiro Uchiyama

1 reference

11 November 2017

Yukito Shinohara

1

1 reference

11 November 2017

Yasuo Katayama

2

1 reference

11 November 2017

Takenori Yamaguchi

4

1 reference

11 November 2017

Shunnosuke Handa

5

1 reference

11 November 2017

Kempei Matsuoka

6

1 reference

11 November 2017

Yasuo Ohashi

7

1 reference

11 November 2017

Norio Tanahashi

8

1 reference

11 November 2017

Hiroko Yamamoto

9

1 reference

11 November 2017

Chokoh Genka

10

1 reference

11 November 2017

Yasuhisa Kitagawa

11

1 reference

11 November 2017

Hideo Kusuoka

12

1 reference

11 November 2017

Katsuya Nishimaru

13

1 reference

11 November 2017

Motoo Tsushima

14

1 reference

11 November 2017

Yukihiro Koretsune

15

1 reference

11 November 2017

Tohru Sawada

16

1 reference

11 November 2017

Chikuma Hamada

17

1 reference

11 November 2017

CSPS 2 group

18

1 reference

11 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20833591

11 July 2024

publication date

15 September 2010

1 reference

full work available at URL

11 November 2017

https://api.elsevier.com/content/article/PII:S1474442210701988?httpAccept=text/xml

1 reference

10.1016/S1474-4422(10)70198-8

DOI

https://api.crossref.org/works/10.1016/S1474-4422(10)70198-8

https://api.elsevier.com/content/article/PII:S1474442210701988?httpAccept=text/plain

11 July 2024

1 reference

10.1016/S1474-4422(10)70198-8

DOI

https://api.crossref.org/works/10.1016/S1474-4422(10)70198-8

11 July 2024

1 reference

11 November 2017

volume

9

1 reference

11 November 2017

issue

10

1 reference

11 November 2017

page(s)

959-968

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Thoughts evoked by MATCH and other trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Tables of the number of patients required in clinical trials using the logrank test.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Venous and arterial thrombosis: a continuous spectrum of the same disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Safety and efficacy of cilostazol in the management of intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in Culture

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970198-8

7 January 2021

10.1016/S1474-4422(10)70198-8

Identifiers

DOI

1 reference

11 November 2017

1 reference